A Pilot Study of Durvalumab (MEDI4736) With Tremelimumab in Combination With Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 04 Jun 2019 Primary endpoint (overall survival) has not been met according to the results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2019 Efficacy results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 08 Apr 2019 Status changed from recruiting to active, no longer recruiting.